Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?

被引：1
|
作者：
Rizzo, Alessandro [1 ]
Palmiotti, Gennaro [1 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med, Presa Carico Globale Paziente Oncol Don Toni, Viale Orazio Flacco 65, I-70124 Bari, Italy
来源：
IMMUNOTHERAPY | 2022年 / 14卷 / 10期
关键词：
atezolizumab; breast cancer; immune checkpoint inhibitors; immunotherapy; pembrolizumab; triple-negative breast cancer; IMMUNOTHERAPY;
D O I：
10.2217/imt-2022-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：755 / 758
页数：4
相关论文
共 50 条
  • [1] Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
    Rizzo, Alessandro
    Cusmai, Antonio
    Massafra, Raffaella
    Bove, Samantha
    Comes, Maria Colomba
    Fanizzi, Annarita
    Rinaldi, Lucia
    Acquafredda, Silvana
    Gadaleta-Caldarola, Gennaro
    Oreste, Donato
    Zito, Alfredo
    Giotta, Francesco
    Lorusso, Vito
    Palmiotti, Gennaro
    CELLS, 2022, 11 (12)
  • [2] Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
    Rizzo, Alessandro
    Cusmai, Antonio
    Gadaleta-Caldarola, Gennaro
    Palmiotti, Gennaro
    MEDICINA-LITHUANIA, 2022, 58 (05):
  • [3] Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
    Seager, Robert J.
    Ko, Heidi
    Pabla, Sarabjot
    Senosain, Maria-Fernanda
    Kalinski, Pawel
    Van Roey, Erik
    Gao, Shuang
    Strickland, Kyle C.
    Previs, Rebecca Ann
    Nesline, Mary K.
    Hastings, Stephanie
    Zhang, Shengle
    Conroy, Jeffrey M.
    Jensen, Taylor J.
    Eisenberg, Marcia
    Caveney, Brian
    Severson, Eric A.
    Ramkissoon, Shakti
    Gandhi, Shipra
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (05):
  • [4] Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
    Liu, Siyan
    Li, Jing
    Gu, Lin
    Wu, Kunzhe
    Xing, Hua
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2022, 17 : 5209 - 5227
  • [5] Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer
    van Dongen, M. G. J.
    Kok, M.
    ANNALS OF ONCOLOGY, 2020, 31 (05) : 556 - 557
  • [6] Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer
    Kakimi, Kazuhiro
    Sugie, Tomoharu
    BREAST CANCER, 2025,
  • [7] KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
    Rizzo, Alessandro
    Cusmai, Antonio
    Acquafredda, Silvana
    Giovannelli, Francesco
    Rinaldi, Lucia
    Misino, Andrea
    Palmiotti, Gennaro
    FUTURE ONCOLOGY, 2022, 18 (18) : 2301 - 2309
  • [8] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
    Boscolo Bielo, Luca
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 789 - 801
  • [9] New strategies for the management of triple-negative breast cancer
    Riaz, Fauzia
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2024, 36 (01) : 40 - 44
  • [10] Pembrolizumab and atezolizumab in triple-negative breast cancer
    Dorota Kwapisz
    Cancer Immunology, Immunotherapy, 2021, 70 : 607 - 617
12345